Clinical Trial Update: A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study to evaluate AR-12286, a Rho-kinase inhibitor ophthalmic solution, at 0.5% and 0.7% in chronic angle-closure g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angle-closure Glaucoma

Drugs mentioned

• AR-12286 ophthalmic solution (AR-12286)

Snippet

Sponsor: New York Glaucoma Research Institute | Conditions: Chronic Angle-closure Glaucoma | Phase 2 | Status: UNKNOWN